'We Believe We Have the Most Valuable Biosimilars Pipeline'

It was a great pleasure to have the chance to sit down the other day with Dave Wallace executive editor of Generics Bulletin, for a wide-ranging conversation about Alvotech and our strategy for bringing important medicines to more people who need them.

I am grateful to Dave for taking the time to meet in person and for such a stimulating conversation. And he has just come out with an extensive piece on how we built Alvotech; how our business is growing; and how our vertically integrated capabilities have given us the most valuable pipeline in the industry and the flexibility to pursue the widest range of opportunities in the months and years ahead.

You can read the piece here.